The £10 Million Mistake: Why Most MedTech Products Fail Before Launch
The MedTech industry is full of brilliant ideas.
Every year, entrepreneurs, clinicians and engineers develop technologies capable of transforming patient care. Yet most never achieve meaningful commercial success.
Not because the science doesn’t work.
Not because the engineering isn’t good enough.
But because critical commercial decisions are made too late.
By the time many companies discover fundamental issues with usability, manufacturing, regulation, reimbursement or adoption, millions of pounds have already been invested and changing direction has become painfully expensive.
It is a mistake that can easily cost £10 million or more.
Great Technology Doesn’t Guarantee a Great Product
Most development programmes begin with the technology.
The challenge is that healthcare doesn’t buy technology. It adopts solutions that solve real clinical and operational problems.
A product may perform exceptionally in laboratory testing while proving almost impossible to manufacture economically, integrate into clinical workflows or gain regulatory approval.
These aren’t engineering failures.
They’re commercial failures.
The earlier these risks are identified, the cheaper they are to solve.
The Cost of Getting It Wrong
Many MedTech companies follow a familiar path.
They spend years refining the technology.
Develop multiple prototypes.
Raise investment.
Complete verification testing.
Begin regulatory activities.
Only then do difficult questions emerge.
Can clinicians use it intuitively?
Does it fit existing workflows?
Will procurement support adoption?
Can it be manufactured at scale?
Does the economics make sense?
Will healthcare providers actually change behaviour?
At this stage, redesigning even relatively small elements of a product can cost millions and delay launch by years.
In some cases, the programme never recovers.
The Most Valuable Prototype Isn’t the Final Product
Many organisations think prototyping is about proving the technology.
In reality, the most valuable prototypes answer commercial questions.
They reduce uncertainty.
They identify hidden risks.
They allow companies to fail quickly, learn quickly and improve quickly, before large investments are committed.
Good prototypes don’t simply prove that something can be built.
They prove it deserves to be built.
Thinking Like a Skunk Works Team
At Maddison, we approach innovation differently.
Rather than spending years perfecting a concept before exposing it to commercial reality, we challenge assumptions from the outset.
Our role is to ask difficult questions early.
What could stop this product succeeding?
Where are the technical risks?
Where are the regulatory risks?
Where are the commercial risks?
How will clinicians actually use it?
Can it be manufactured efficiently?
Can it scale internationally?
How quickly can we test these assumptions?
This is classic skunk works thinking.
Small, highly experienced multidisciplinary teams solving the hardest problems quickly, before complexity and cost spiral out of control.
It is often faster to spend six weeks proving an idea won’t work than two years proving it does.
Reducing Risk Before It Becomes Expensive
The biggest opportunities to save time and money exist right at the beginning of development.
That’s where early strategy and rapid iteration create the greatest value.
Our approach combines:
- Commercial strategy
- Human-centred design
- Rapid concept development
- Industrial design
- Engineering feasibility
- Usability engineering
- Regulatory thinking
- Design for manufacture
- Clinical workflow assessment
- Early stakeholder validation
Each discipline informs the others.
Instead of progressing through isolated development stages, we build confidence across the entire product journey simultaneously.
Building Products Investors Want to Back
Investors increasingly look beyond the technology itself.
They want confidence that products can reach market efficiently and generate commercial returns.
They ask questions such as:
- Is there genuine clinical demand?
- Can the product navigate regulation?
- Will healthcare providers adopt it?
- Is manufacturing scalable?
- Is the route to reimbursement understood?
- Can the business defend its competitive position?
Answering these questions early makes companies significantly more attractive to investors and strategic partners.
Commercialisation Starts on Day One
Commercial strategy isn’t something that begins after product development.
It should shape product development from the very beginning.
The strongest MedTech companies don’t separate innovation from commercialisation.
They develop products with adoption, scalability and market success built into every decision.
Where Maddison Fits
Maddison isn’t simply a product design consultancy.
We’re a healthcare innovation skunk works.
We work alongside ambitious MedTech companies to challenge assumptions, remove risk and accelerate commercial success.
Our multidisciplinary team brings together strategy, industrial design, engineering, human factors and commercial thinking to solve the problems that determine whether products succeed in the real world.
Because the most expensive mistake in MedTech isn’t building the wrong product.
It’s discovering you’ve built the wrong product after spending £10 million getting there.